Pancreatic cancer is one of the most lethal malignancies, with a 5-year survival of 8%.
| INTRODUC TI ON
Pancreatic cancer is one of the most lethal malignancies, with a 5-year survival of 8%. 1 There is currently no effective treatment for metastatic PC. 1 Investigating the genetic and epigenetic landscape of PC would improve our understanding of the molecular mechanisms underlying its initiation, aggressive progression, and therapy resistance and would lead to better prevention, diagnosis, and treatment of PC.
Long noncoding RNAs refer to noncoding RNAs that are more than 200 nt in length. They have received considerable attention in recent years because of their potential to regulate diverse biological processes such as tumor progression and metastasis. 2 According to regulatory mechanisms on the expression of target genes, lncRNAs can work as signals, decoys, scaffolds, guides, and competing endogenous RNAs. 3 The lncRNA DLEU2 is transcribed from chromosome 13q14. 3; 4 it is highly expressed in PC samples compared to normal tissues. 5, 6 However, the role and the molecular mechanisms of DLEU2 in PC remain elusive. In this study, we aimed to explore the role and the underlying mechanisms of DLEU2 during PC progression. We showed that DLEU2 was overexpressed in PC, and it promoted cancer cell proliferation and invasion through modulating the miR-455/SMAD2 pathway.
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Long noncoding RNA (lncRNA) DLEU2 has been shown to be dysregulated in several type of tumor. However, the potential biological roles and molecular mechanisms of DLEU2 in pancreatic cancer (PC) progression are poorly understood. In this study, we found that the DLEU2 level was substantially upregulated in PC tissues and PC cell lines, and significantly associated with poor clinical outcomes in PC patients.
Overexpression of DLEU2 significantly induced PC cell proliferation and invasion, whereas knockdown of DLEU2 impaired cell proliferation and invasion in vitro.
Furthermore, bioinformatics analysis, luciferase reporter assay, and RNA immunoprecipitation assay revealed that DLEU2 directly bond to microRNA-455 (miR-455) and functioned as an endogenous sponge for miR-455, which could remarkably suppress cell growth and invasion. We also determined that SMAD2 was a direct target of miR-455, and the restoration of SMAD2 rescued cell growth and invasion that were reduced by DLEU2 knockdown or miR-455 overexpression. In addition, low miR-455 expression and high SMAD2 expression was correlated with poor patient survival. These results indicate that DLEU2 is an important promoter of PC development, and targeting the DLEU2/miR-455/SMAD2 pathway could be a promising therapeutic approach in the treatment of PC.
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| MATERIAL S AND ME THODS

| Cell lines and transfection
| RNA extraction and qRT-PCR assay
Total RNA was extracted using TRIzol reagent (Invitrogen) according to the manufacturer's instructions. RNA was reverse transcribed using the PrimeScript RT reagent Kit (Takara Japan, Tokyo, Japan).
The qPCR analysis was carried out using SYBR Premix EX Taq (Takara China, Dalian, China). GAPDH was used as an internal control for lncRNA. The primers for DLEU2 and GAPDH have been reported. 7 The mirVana qRT-PCR microRNA Detection Kit (Ambion, Austin, TX, USA) was used for miR-455 detection according to the manufacturer's instructions. The primers for miR-455 were obtained from RiboBio. Human U6 RNA was used as an internal control for miRNA.
The results were analyzed and expressed relative to threshold cycle values and converted to fold changes. Experiments were repeated at least 3 times.
| Western blot analysis
The entire protein lysates were split by 10% SDS-PAGE. The split protein was transferred into a PVDF membrane (Millipore, Bedford, MA, USA). The above membranes were incubated with the primary Abs SMAD2 (1:1000 dilution; Abcam, Cambridge, UK) and GAPDH
(1:1000 dilution; Santa Cruz Biotechnology, Santa Cruz, CA, USA) overnight. The membranes were then treated with secondary Ab conjugated to HRP for 2 hours at room temperature. Detection was undertaken using an ECL western blotting kit (Amersham Biosciences, Little Chalfont, UK). GAPDH was used as the loading control. The intensities of protein bands were quantitated using ImageJ software (National Institutes of Health, Bethesda, MD, USA).
| Proliferation assay
The CCK-8 assay (Beyotime Institute of Biotechnology, Jiangsu, China) was applied to evaluate cell proliferation. Pancreatic cancer cells (5 × 10 3 cells per well in 96-well plates) were transfected and cell proliferation was recorded 72 hours after transfection following the manufacturer's instructions. The absorbance was measured at 450 nm by a microplate reader (Bio-Rad, Hercules, CA, USA).
| Invasion assay
The invasion assay was carried out using Transwell chambers (24 wells; Corning, Tewksbury, MA, USA) and a previously described protocol. 8, 9 Cells (2 × 10 4 ) were seeded on the top side of the Transwell filter coated with Matrigel in the chamber. Cells were suspended in the serum-free medium. The medium supplemented with 10% FBS was added into the lower chamber. After culturing for 24 hours, cells that had invaded the membrane were fixed with 75% methanol and stained with 0.1% crystal violet. The number of invaded cells was observed using an inverted microscope and calculated by counting 5 random views. All experiments were carried out in triplicate.
| Luciferase assay
The fragment of WT DLEU2 (DLEU2-WT) containing the predicted po- as a negative control. Samples were digested with proteinase K, and RNAs were isolated from the immunoprecipitation products.
| RNA immunoprecipitation assay
Ultimately, the qRT-PCR assay was utilized to detect the expression of DLEU2 and GAPDH. GAPDH mRNA was used as the negative control.
| Statistical analysis
We used the SPSS 20.0 statistical software (IBM, Armonk, NY, USA) to statistically analyze the results. Data are presented as the mean ± SD from at least 3 experiments. The significant differences were analyzed using Student's t test or one-way ANOVA. P-value < .05 was regarded as significant.
| RE SULTS
| DLEU2 is upregulated in PC cell lines and PC tissues
First, we examined DLEU2 expression in PC tissues and normal pancreatic tissues using the web-based Oncomine microarray database (https:// www.oncomine.org), and found that DLEU2 expression is elevated in PC tissues in comparison to normal pancreatic tissues ( Figure 1A ). Then the expression levels of DLEU2 were examined in PC tissues and normal pancreatic tissues using The Cancer Genome Atlas data through the web portal of UALCAN (http://ualcan.path.uab.edu/). We found that the DLEU2 expression was significantly higher in PC than corresponding normal tissues ( Figure 1B ). Then we measured the expression of DLEU2 in PC cell lines (AsPC-1 and PaCa-2) compared with normal pancreatic cell line HPDE6-C7 using qRT-PCR analysis. Our results indicated that
AsPC-1 and PaCa-2 cells had higher levels of DLEU2 expression than the normal cell line HPDE6-C7 ( Figure 1C ). We also used the UALCAN portal to investigate the relationship between DLEU2 expression and patient survival. 10 Kaplan-Meier analysis revealed that higher DLEU2 expression was associated with poor survival of patients with PC ( Figure 1F ).
| DLEU2 promotes PC cell proliferation and invasion in vitro
We analyzed the expression of DLEU2 transcript variants in 178 patients with PC using RNA sequencing data available from the were examined using quantitative real-time PCR analysis. E, Images and quantification of SMAD2 protein expression levels in PC cell lines and normal cell line HPDE6-C7 by western blot analysis. GAPDH was used as a normalization control. F, Survival curve for patients with high or low DLEU2 expression using the online tool UALCAN. *P < .05
ISOexpresso database. 11 We found that 9 DLEU2 transcript variants and a short variant of DLEU2 (uc001vdy.3, hg19; chr13:50,618,048-50,656,139) are predominantly expressed in PC tissues ( Figure 2A ).
These results suggested that uc001vdy.3 is the major variant among all variants in PC samples, and we focused on this variant in this study.
To MicroRNA-15a and miR-16 are encoded within the intronic region of DLEU2. 12 The expression of miR-15a and miR-16 were reduced in PC samples and they were shown to act as tumor suppressors in PC. [13] [14] [15] We explored the roles of miR-15a and miR-16 Recent studies have proposed that the expression and function of some intronic miRNAs could be the opposite to that of their host genes. 16 Intronic miRNAs can potentially influence the expression and function of their host genes. 17 Therefore, we investigated whether miR-15a and miR-16 could influence the expression of DLEU2 in PC cells. The qRT-PCR results suggested that overexpression of miR-15a and miR-16 resulted in significant reduction of DLEU2 levels ( Figure 3D ). Collectively, these data indicated that miR-15a and miR-16 inhibit cell proliferation and invasion and might regulate the expression of their host gene DLEU2 in PC cells.
| DLEU2 promotes PC cell proliferation and invasion by acting as a sponge of miR-455
Many lncRNAs are known to contain motifs with sequences complementary to miRNAs and can inhibit miRNA expression and activity. 18 To determine whether DLEU2 affects the behavior of PC cells by functioning as a molecular sponge of miRNA, we used the public prediction algorithm StarBase V2.0 to predict the potential miRNA binding sites in DLEU2. 19 We identified a miR-455-binding site in 
| MicroRNA-455 directly targets SMAD2 in PC cells
To further explore the mechanism through which miR-455 exerts its tumor suppressive role in PC, we predicted the potential targets of miR-455 using multiple algorisms (including TargetScan, partly abolished this effect (Fig. 5E ). The induction of SMAD2 expression caused by DLEU2 overexpression could be largely reversed by the transfection of miR-455 mimic in AsPC-1 cells (Fig. 5E ).
Altogether, these results suggested that DLEU2 could promote the expression of oncogene SMAD2 by competitively binding to tumor suppressor miR-455.
We investigated the mRNA expression of SMAD2 between PC and normal tissues using the Oncomine database. This analysis revealed that SMAD2 was up-regulated in PC samples ( Figure 1A whereas miR-455 knockdown increased the luciferase activities of WT SMAD2 3′-UTR in AsPC-1 cells ( Figure 5C ). However, miR-455 did not change the luciferase activities of mutant SMAD2 3′-UTR ( Figure 5C ). Moreover, western blot analysis showed that miR-455 overexpression inhibited the protein level of SMAD2 in PC cells, whereas miR-455 knockdown increased it ( Figure 5D ).
We examined the association of miR-455 and SMAD2 expression and overall survival rate in PC patients using the online survival analysis tool KM plotter (http://kmplot.com/analysis/). Lower miR-455 expression or higher SMAD2 expression correlates with reduced overall survival in PC patients ( Figure 6 ). These data showed that SMAD2 was a downstream target of miR-455.
| Restoration of SMAD2 reversed the effects of DLEU2 knockdown and miR-455 overexpression
To further confirm that the effects of DLEU2 and miR-455 on PC cells were dependent on the expression of SMAD2, we restored 
| D ISCUSS I ON
Long noncoding RNA DLEU2 is downregulated in leukemia 12 and laryngeal carcinoma. 20 However, it was found to be elevated in renal cell carcinoma cells, and higher expression of DLEU2 was associated with a poor prognosis in patients with renal cell carcinoma. 21 These previous results indicated that DLEU2 might have distinct functions in different tumors but did not provide enough information about the biological activity and mechanism by which DLEU2 regulates carcinogenesis and progression of human tumors (including PC). In this study, our findings showed that upregula- Recent studies have revealed that there is an interplay and cross-regulation between lncRNAs and miRNAs. 24 Long noncoding RNAs might function as molecular sponges in modulating miRNAs. 24 Importantly, DLEU2 could act as an endogenous sponge by directly binding to miR-30a in renal cell carcinoma. 21 Here, we confirmed the existence of an interaction between DLEU2 and miR-455 in PC cells.
We showed that DLEU2 directly binds to miR-455, resulting in an induction of the mRNA targets of miR-455 (such as SMAD2) and facilitating the proliferation and invasion of PC cells.
Numerous studies have reported a tumor suppressive role for miR-455 in many tumors, including melanoma, 25 colorectal cancer, 26 lung cancer, 27 gastric cancer 28 and prostate cancer. 29 MicroRNA-455 was reported to be downregulated in PC tissues and cell lines and inhibits the proliferation of PC cells. 30 In the present study, we reported that miR-455 could significantly suppress PC cell growth and invasion. Furthermore, we showed that miR-455 overexpression abrogated DLEU2-mediated PC cell proliferation and invasion, suggesting that miR-455 could be an important downstream regulator of DLEU2 function.
SMADs can integrate multiple signaling pathways and regulate the expression of target genes in transforming growth factor-β-activated cells. 31 In PC cells, SMAD2 overexpression could increase proliferation and invasion. 32 Identification of the upstream regulators of SMAD2 will help elucidate its critical role in tumorigenesis.
Our present study showed that miR-455 interacts with SMAD2 to repress its expression in PC cells. Thus, interactions between DLEU2, miR-455, and SMAD2 might be biologically significant in the network regulating PC aggressiveness.
In conclusion, we show for the first time that upregulation of DLEU2 acts as an oncogenic driver in PC through modulating the miR-455/SMAD2 axis. Therefore, our results provide the basis for a novel therapeutic strategy to target the DLEU2/miR-455/SMAD2 axis in PC.
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